Mediscience completes acquisition of SensiVida Medical Systems

Mediscience Technology, a developer of minimally invasive autofluorescent-based technology for early detection of cancer, has expanded its technology platform with the completion of the acquisition of SensiVida Medical Systems, a biomedical diagnostic company. The merged entity is named Sensivida Medical Technologies.

David Smith has been appointed as chairman of the new board of directors. Kamal Sarbadhikari and Jose Mir are appointed as the president and CEO and the chief technology officer of the company, respectively. Peter Katevatis resigned as CEO, treasurer and chairman of the Mediscience board and continues as a director of SensiVida Medical Technologies’s new board.

Mr Sarbadhikari is an entrepreneurial senior executive with 40 years of start-up and management of Fortune 1000 companies. Prior to SensiVida, he ran Bausch and Lomb’s surgical businesses. He was part of the original team responsible for commercializing soft-contact lenses.

Mr Mir started his career at the Eastman Kodak Company, pioneering new technologies that enabled some of the world’s earliest digital imaging products. Most recently, he founded SensiVida Medical Systems and served as its president/chief technology officer for three years.

Mr Smith is a founding member of Infotonics Technology Center and served as its president, CEO and chairman of the board from 2002 to 2008.